IRONWOOD PHARMACEUTICALS, INC. Payments to Acquire Available-for-sale Securities
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Payments to Acquire Available-for-sale Securities of $191.35 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-02-22.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2018-02-22
- IRONWOOD PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for the quarter ending 2017-12-31 was $60.63M, a 59.01% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for the quarter ending 2017-09-30 was $40.02M, a 63.81% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for the quarter ending 2017-06-30 was $45.93M.
- IRONWOOD PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for the quarter ending 2017-03-31 was $44.78M, a 14.92% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for fiscal 2017 was $191.35M, a 38.49% decline from fiscal 2016.
- IRONWOOD PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for fiscal 2016 was $311.12M, a 10.34% increase from fiscal 2015.
- IRONWOOD PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for fiscal 2015 was $281.96M, a 11.01% increase from fiscal 2014.
- IRONWOOD PHARMACEUTICALS, INC. payments to acquire available-for-sale securities for fiscal 2014 was $254.00M, a 11.79% decline from fiscal 2013.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month | Payments to Acquire Available-for-sale Securities 12 month |
|---|---|---|---|---|
| 2017-12-31 | $60.63M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | $100.65M derived: sum of 2 quarters · filed 2018-02-22 | $146.58M derived: sum of 3 quarters · filed 2018-02-22 | $191.35M 10-K · filed 2018-02-22 |
| 2017-09-30 | $40.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $85.95M derived: sum of 2 quarters · filed 2017-11-02 | $130.73M 10-Q · filed 2017-11-02 | $278.62M derived: sum of 4 quarters · filed 2018-02-22 |
| 2017-06-30 | $45.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $90.71M 10-Q · filed 2017-08-03 | $238.59M derived: sum of 3 quarters · filed 2018-02-22 | $349.19M derived: sum of 4 quarters · filed 2018-02-22 |
| 2017-03-31 | $44.78M 10-Q · filed 2017-05-08 | $192.66M derived: sum of 2 quarters · filed 2018-02-22 | $303.26M derived: sum of 3 quarters · filed 2018-02-22 | $303.26M derived: sum of 4 quarters · filed 2018-02-22 |
| 2016-12-31 | $147.89M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | $258.49M derived: sum of 2 quarters · filed 2018-02-22 | $258.49M derived: sum of 3 quarters · filed 2018-02-22 | $311.12M 10-K · filed 2018-02-22 |
| 2016-09-30 | $110.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $110.60M derived: sum of 2 quarters · filed 2017-11-02 | $163.23M 10-Q · filed 2017-11-02 | $192.32M derived: sum of 4 quarters · filed 2018-02-22 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $52.63M 10-Q · filed 2017-08-03 | $81.72M derived: sum of 3 quarters · filed 2018-02-22 | $132.50M derived: sum of 4 quarters · filed 2018-02-22 |
| 2016-03-31 | $52.63M 10-Q · filed 2017-05-08 | $81.72M derived: sum of 2 quarters · filed 2018-02-22 | $132.50M derived: sum of 3 quarters · filed 2018-02-22 | $262.31M derived: sum of 4 quarters · filed 2018-02-22 |
| 2015-12-31 | $29.09M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-22 | $79.87M derived: sum of 2 quarters · filed 2018-02-22 | $209.68M derived: sum of 3 quarters · filed 2018-02-22 | $281.96M 10-K · filed 2018-02-22 |
| 2015-09-30 | $50.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $180.58M derived: sum of 2 quarters · filed 2016-11-07 | $252.87M 10-Q · filed 2016-11-07 | $266.00M derived: sum of 4 quarters · filed 2017-02-22 |
| 2015-06-30 | $129.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-08 | $202.09M 10-Q · filed 2016-08-08 | $215.22M derived: sum of 3 quarters · filed 2017-02-22 | $249.14M derived: sum of 4 quarters · filed 2017-02-22 |
| 2015-03-31 | $72.28M 10-Q · filed 2016-05-10 | $85.41M derived: sum of 2 quarters · filed 2017-02-22 | $119.33M derived: sum of 3 quarters · filed 2017-02-22 | $246.58M derived: sum of 4 quarters · filed 2017-02-22 |
| 2014-12-31 | $13.13M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-22 | $47.05M derived: sum of 2 quarters · filed 2017-02-22 | $174.30M derived: sum of 3 quarters · filed 2017-02-22 | $254.00M 10-K · filed 2017-02-22 |
| 2014-09-30 | $33.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $161.17M derived: sum of 2 quarters · filed 2015-11-05 | $240.86M 10-Q · filed 2015-11-05 | $321.50M derived: sum of 4 quarters · filed 2016-02-19 |
| 2014-06-30 | $127.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | $206.94M 10-Q · filed 2015-08-07 | $287.58M derived: sum of 3 quarters · filed 2016-02-19 | $350.30M derived: sum of 4 quarters · filed 2016-02-19 |
| 2014-03-31 | $79.70M 10-Q · filed 2015-05-06 | $160.33M derived: sum of 2 quarters · filed 2016-02-19 | $223.06M derived: sum of 3 quarters · filed 2016-02-19 | $248.77M derived: sum of 4 quarters · filed 2016-02-19 |
| 2013-12-31 | $80.64M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | $143.36M derived: sum of 2 quarters · filed 2016-02-19 | $169.07M derived: sum of 3 quarters · filed 2016-02-19 | $287.94M 10-K · filed 2016-02-19 |
| 2013-09-30 | $62.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | $88.44M derived: sum of 2 quarters · filed 2014-11-05 | $207.31M 10-Q · filed 2014-11-05 | $243.12M derived: sum of 4 quarters · filed 2015-02-18 |
| 2013-06-30 | $25.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $144.58M 10-Q · filed 2014-08-05 | $180.40M derived: sum of 3 quarters · filed 2015-02-18 | $196.64M derived: sum of 4 quarters · filed 2015-02-18 |
| 2013-03-31 | $118.87M 10-Q · filed 2014-04-29 | $154.68M derived: sum of 2 quarters · filed 2015-02-18 | $170.92M derived: sum of 3 quarters · filed 2015-02-18 | $192.24M derived: sum of 4 quarters · filed 2015-02-18 |
| 2012-12-31 | $35.81M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-18 | $52.05M derived: sum of 2 quarters · filed 2015-02-18 | $73.37M derived: sum of 3 quarters · filed 2015-02-18 | $96.71M 10-K · filed 2015-02-18 |
| 2012-09-30 | $16.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-28 | $37.56M derived: sum of 2 quarters · filed 2013-10-28 | $60.90M 10-Q · filed 2013-10-28 | $76.88M derived: sum of 4 quarters · filed 2014-02-07 |
| 2012-06-30 | $21.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-08 | $44.66M 10-Q · filed 2013-08-08 | $60.64M derived: sum of 3 quarters · filed 2014-02-07 | $85.08M derived: sum of 4 quarters · filed 2014-02-07 |
| 2012-03-31 | $23.34M 10-Q · filed 2013-04-23 | $39.33M derived: sum of 2 quarters · filed 2014-02-07 | $63.77M derived: sum of 3 quarters · filed 2014-02-07 | $81.41M derived: sum of 4 quarters · filed 2014-02-07 |
| 2011-12-31 | $15.99M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-07 | $40.43M derived: sum of 2 quarters · filed 2014-02-07 | $58.08M derived: sum of 3 quarters · filed 2014-02-07 | $97.51M 10-K · filed 2014-02-07 |
| 2011-09-30 | $24.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $42.09M derived: sum of 2 quarters · filed 2012-11-06 | $81.52M 10-Q · filed 2012-11-06 | $201.00M derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-06-30 | $17.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | $57.08M 10-Q · filed 2012-08-07 | $176.56M derived: sum of 3 quarters · filed 2013-02-21 | $224.75M derived: sum of 4 quarters · filed 2013-02-21 |
| 2011-03-31 | $39.44M 10-Q · filed 2012-05-10 | $158.92M derived: sum of 2 quarters · filed 2013-02-21 | $207.10M derived: sum of 3 quarters · filed 2013-02-21 | |
| 2010-12-31 | $119.48M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | $167.67M derived: sum of 2 quarters · filed 2013-02-21 | $441.80M 10-K · filed 2013-02-21 | |
| 2010-09-30 | $48.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-09 | $322.32M 10-Q · filed 2011-11-09 | ||
| 2010-06-30 | $274.13M 10-Q · filed 2011-08-12 | |||
| 2009-12-31 | $26.67M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |